Cited by 187Advanced Glycation End Products researchGlycosylation and Glycoproteins ResearchGalectins and Cancer Biology

The Receptor for Advanced Glycation End Products (RAGE) Specifically Recognizes Methylglyoxal-Derived AGEs

Open access
Xue, Jing, Ray, Rashmi, Singer, David, Böhme, David, Burz, David S., Rai, Vivek, Hoffmann, Ralf, Shekhtman, Alexander·2014·Biochemistry

Abstract

Diabetes-induced hyperglycemia increases the extracellular concentration of methylglyoxal. Methylglyoxal-derived hydroimidazolones (MG-H) form advanced glycation end products (AGEs) that accumulate in the serum of diabetic patients. The binding of hydroimidozolones to the receptor for AGEs (RAGE) results in long-term complications of diabetes typified by vascular and neuronal injury. Here we show that binding of methylglyoxal-modified albumin to RAGE results in signal transduction. Chemically synthesized peptides containing hydroimidozolones bind specifically to the V domain of RAGE with nanomolar affinity. The solution structure of an MG-H1–V domain complex revealed that the hydroimidazolone moiety forms multiple contacts with a positively charged surface on the V domain. The high affinity and specificity of hydroimidozolones binding to the V domain of RAGE suggest that they are the primary AGE structures that give rise to AGEs–RAGE pathologies.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1021/bi500046t

Cites

46 of 46 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The interaction of AGE-RAGE triggers intracellular and extracellular signaling pathways through activation of ERK1/2, MAPK, PI3K, AKT, NADPH oxidase, and NF-κB.

    “The interaction of AGE-RAGE triggers intracellular and extracellular signaling pathways through the activation of extracellular signal-regulated kinases 1 and 2 (ERK1/2), mitogen-activated protein kinases (MAPK), phosphoinositide 3-kinase (PI3K), protein kinase B (AKT), NADPH oxidase, and nuclear factor-κB (NF-κB).”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

1 retracted

Flagged first, then by citations

1 of the 47 references couldn’t be matched to a known paper.

Research works printed but not linked: 2

  1. Schmidt A. M.; Stern D. M. (2001) Receptor for age (RAGE) is a gene within the major histocompatibility class III region: Implications for host response mechanisms in homeostasis and chronic disease. Front. Biosci. 6, D1151– D1160. 11578972
  2. Schuttelkopf A. W.; van Aalten D. M. (2004) PRODRG: A tool for high-throughput crystallography of protein-ligand complexes. Acta Crystallogr. D60, 1355– 1363. 15272157

Cited by

Sorted by citations

Authors
Xue, J., Ray, R., Singer, D., Böhme, D., Burz, D. S., Rai, V., Hoffmann, R., & Shekhtman, A.
Affiliations
  • State University of New York (US)
  • Institute of Life Sciences (IN)
  • Leipzig University (DE)
  • Universität Leipzig , , ,
Corresponding author
Shekhtman, Alexander
Venue
Biochemistry
Published
2014-05-05
Volume
53
Issue
20
Pages
3327-3335
ISSN
  • 0006-2960 (ISSN-L)
  • 1520-4995
OpenAlex
W2075351997
Cited by
186
References
47
Citations by year
2026: 8 · 2025: 13 · 2024: 14 · 2023: 18 · 2022: 22 · 2021: 22 · 2020: 16 · 2019: 19 · 2018: 7 · 2017: 14 · 2016: 14 · 2015: 15 · 2014: 4
FWCI
10.84
Type
journal article
Language
en
Open access
Locations
  • Biochemistry (publishedVersion, other-oa)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
National Institute of General Medical Sciences (R01GM085006)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Advanced Glycation End Products research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Glycosylation and Glycoproteins Research
  • Life Sciences › Immunology and Microbiology › Immunology › Galectins and Cancer Biology
Keywords
receptor for advanced glycation end products, RAGE, methylglyoxal, hydroimidazolone, advanced glycation end products, V domain, signal transduction, peptide binding, protein-protein complex structure, diabetes complications, hyperglycemia
MeSH terms
Receptor for Advanced Glycation End Products, Cell Line, Humans, Pyruvaldehyde, Receptors, Immunologic, Signal Transduction, Glycation End Products, Advanced, Protein Structure, Secondary, Protein Structure, Tertiary

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review